CTLT241220C50000
- 11.78
- 0.000.00%
Catalent Newsroom
Morgan Stanley Lists Hedge Funds' Largest Q3 Ownership Increases in Russell 1000 Stocks
US Manufacturing Index Rises To 43, Highest Since 2020
EU regulatory institutions are inquiring about Novo Nordisk's acquisition of catalent.
According to sources, on November 14, the European Union's antitrust regulatory agency has requested feedback from pharmaceutical industry competitors and customers on four business areas regarding Novo Holdings' plan to invest $16.5 billion in acquiring Catalent. Novo Holdings, the controlling shareholder of Danish pharmaceutical company Novo Nordisk A/S, has become the highest market cap company in Europe driven by the generous profits from the popular weight loss drug Wegovy. While survey results show that the European Commission is seeking market insights, it may allow competitors and customers to raise potential antitrust concerns.
EU Regulators See Info From Rivals, Customers in Catalent Sale to Novo Holdings - Reuters
EU Regulators Quiz Novo Nordisk, Catalent Rivals on $16.5 Billion Deal
Medical stocks collectively surged! Bullish news has arrived, the medical sector welcomes a catalyst.
The medical sector with lagging growth finally sees a catalyst! Analysis believes that for medical institutions, prepayment of medical insurance funds helps optimize and improve the daily operation cash flow and financial pressure of medical institutions, reducing the potential receivables and bad debt risks caused by unpaid medical insurance expenses. For medical insurance, it enhances the settlement efficiency and encourages the active diagnosis and treatment enthusiasm of medical institutions.
Barclays Maintains Catalent(CTLT.US) With Hold Rating, Maintains Target Price $63
Analysts Have Conflicting Sentiments on These Healthcare Companies: Catalent (CTLT), Moderna (MRNA) and HCA Healthcare (HCA)
Jefferies Maintains Catalent(CTLT.US) With Hold Rating, Maintains Target Price $63.5
Catalent's Biologics Underperformance and PCH Stability Lead to Hold Rating
Novo Nordisk CFO: Believe Catalent Deal Will Close by Yr-End Based on Regulator Interactions
Catalent | 10-Q: Q1 2025 Earnings Report
Catalent Misses Q1 Revenue Estimates Ahead of $16.5 Billion Deal Close With Novo Holdings
Catalent (CTLT) Reports Q1 Loss, Lags Revenue Estimates
Catalent | 8-K: Catalent, Inc. Reports First Quarter Fiscal 2025 Results
Catalent Inc. Q1 Loss Narrows
Express News | Catalent - Qtrly Loss per Share $0.71
Catalent Q1 2025 Adj EPS $(0.13) May Not Be Comparable To $0.05 Estimate, Sales $1.02B Miss $1.06B Estimate
Express News | Catalent - Will No Longer Provides Forward-Looking Guidance
Express News | Catalent, Inc. Reports First Quarter Fiscal 2025 Results